UFIS-SWE-IG
0.1.0 - ci-build

UFIS-SWE-IG, published by UNICOM. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/ufis-swe-ig/ and changes regularly. See the Directory of published versions

: Oxascand-15mg-Tablet-SE-IS-RA - JSON Representation

Raw json | Download


{
  "resourceType" : "RegulatedAuthorization",
  "id" : "Oxascand-15mg-Tablet-SE-IS-RA",
  "meta" : {
    "profile" : [
      🔗 "http://unicom-project.eu/fhir/StructureDefinition/PPLRegulatedAuthorization"
    ]
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: RegulatedAuthorization Oxascand-15mg-Tablet-SE-IS-RA</b></p><a name=\"Oxascand-15mg-Tablet-SE-IS-RA\"> </a><a name=\"hcOxascand-15mg-Tablet-SE-IS-RA\"> </a><a name=\"hcOxascand-15mg-Tablet-SE-IS-RA-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/fhir/marketingAuthorizationNumber</code>/11083</p><p><b>subject</b>: <a href=\"MedicinalProductDefinition-Oxascand-15mg-Tablet-SE-IS-MPD.html\">MedicinalProductDefinition: identifier = http://ema.europa.eu/fhir/mpId#SE-100001594-00011083,http://ema.europa.eu/fhir/eurdId#2234; domain = Human use; status = Current; combinedPharmaceuticalDoseForm = Tablet; indication = Oxascand påverkar de vid ångestsyndrom vanliga symtomen: ängslan, ångest, rastlöshet och  sömnsvårigheter. Vid depressioner med inslag av nyss nämnda symtom kan Oxascand användas  tillsammans med sedvanliga antidepressiva farmaka. Delirium tremens, predeliriösa tillstånd och akuta abstinenssymtom som ångest, spänning och  excitation i samband med alkoholmissbruk.; legalStatusOfSupply = Medicinal product subject to special medical prescription; classification = N05BA04</a></p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/v1/lists/220000000060 220000000061}\">Marketing Authorisation</span></p><p><b>region</b>: <span title=\"Codes:{https://spor.ema.europa.eu/v1/lists/100000000002 100000000535}\">Kingdom of Sweden</span></p><p><b>status</b>: <span title=\"Codes:{https://spor.ema.europa.eu/v1/lists/100000072049 100000072099}\">Valid</span></p><p><b>statusDate</b>: 1990-02-02</p><p><b>holder</b>: <a href=\"Organization-LOC-100001602.html\">Organization Teva Sweden AB</a></p><h3>Cases</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Date[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://ema.europa.eu/fhir/authorisationDateType dateOfFirstAuthorisation}\">First Authorisation</span></td><td>1990-02-02</td></tr></table></div>"
  },
  "identifier" : [
    {
      "system" : "http://ema.europa.eu/fhir/marketingAuthorizationNumber",
      "value" : "11083"
    }
  ],
  "subject" : [
    {
      🔗 "reference" : "MedicinalProductDefinition/Oxascand-15mg-Tablet-SE-IS-MPD"
    }
  ],
  "type" : {
    "coding" : [
      {
        "system" : "https://spor.ema.europa.eu/v1/lists/220000000060",
        "code" : "220000000061",
        "display" : "Marketing Authorisation"
      }
    ]
  },
  "region" : [
    {
      "coding" : [
        {
          "system" : "https://spor.ema.europa.eu/v1/lists/100000000002",
          "code" : "100000000535",
          "display" : "Kingdom of Sweden"
        }
      ]
    }
  ],
  "status" : {
    "coding" : [
      {
        "system" : "https://spor.ema.europa.eu/v1/lists/100000072049",
        "code" : "100000072099",
        "display" : "Valid"
      }
    ]
  },
  "statusDate" : "1990-02-02",
  "holder" : {
    🔗 "reference" : "Organization/LOC-100001602"
  },
  "case" : {
    "type" : {
      "coding" : [
        {
          "system" : "https://ema.europa.eu/fhir/authorisationDateType",
          "code" : "dateOfFirstAuthorisation",
          "display" : "First Authorisation"
        }
      ]
    },
    "dateDateTime" : "1990-02-02"
  }
}